2
|
Boskovic ZV, Kemp MM, Freedy AM, Viswanathan VS, Pop MS, Fuller JH, Martinez NM, Figueroa Lazú SO, Hong JA, Lewis TA, Calarese D, Love JD, Vetere A, Almo SC, Schreiber SL, Koehler AN. Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile. ACS Chem Biol 2016; 11:1844-51. [PMID: 27064299 DOI: 10.1021/acschembio.6b00012] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Unbiased binding assays involving small-molecule microarrays were used to identify compounds that display unique patterns of selectivity among members of the zinc-dependent histone deacetylase family of enzymes. A novel, hydroxyquinoline-containing compound, BRD4354, was shown to preferentially inhibit activity of HDAC5 and HDAC9 in vitro. Inhibition of deacetylase activity appears to be time-dependent and reversible. Mechanistic studies suggest that the compound undergoes zinc-catalyzed decomposition to an ortho-quinone methide, which covalently modifies nucleophilic cysteines within the proteins. The covalent nature of the compound-enzyme interaction has been demonstrated in experiments with biotinylated probe compound and with electrospray ionization-mass spectrometry.
Collapse
Affiliation(s)
- Zarko V. Boskovic
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
- Department
of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| | - Melissa M. Kemp
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
| | - Allyson M. Freedy
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
- Department
of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| | - Vasanthi S. Viswanathan
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
| | - Marius S. Pop
- Koch
Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Department
of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| | - Jason H. Fuller
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
| | - Nicole M. Martinez
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
| | - Samuel O. Figueroa Lazú
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
| | - Jiyoung A. Hong
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
- Koch
Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Division
of Hematology/Oncology, Boston Children’s Hospital, Boston, Massachusetts 02116, United States
| | - Timothy A. Lewis
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
| | - Daniel Calarese
- Department
of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States
| | - James D. Love
- Department
of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States
| | - Amedeo Vetere
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
| | - Steven C. Almo
- Department
of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States
| | - Stuart L. Schreiber
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
- Department
of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States
| | - Angela N. Koehler
- Center
for the Science of Therapeutics, Broad Institute, Cambridge, Massachusetts 02142, United States
- Koch
Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
- Department
of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
6
|
Antitumor, antioxidant and antimicrobial studies of substituted pyridylguanidines. Molecules 2013; 18:10378-96. [PMID: 23985956 PMCID: PMC6269704 DOI: 10.3390/molecules180910378] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2013] [Revised: 07/23/2013] [Accepted: 07/26/2013] [Indexed: 11/17/2022] Open
Abstract
A series of N-pivaloyl-N′-(alkyl/aryl)-N″-pyridylguanidine of general formula C4H9CONHC(NR1R2)NPy have been synthesized and characterized using elemental analysis, FT-IR, multinuclear NMR spectroscopy, and in the case of compounds 7 and 11, by single crystal X-ray diffraction (XRD). The synthesized guanidines were tested for antitumor activities against potato tumor, and showed excellent inhibition against Agrobacterium tumefaciens (AT10)-induced tumor. The antioxidant and antimicrobial activities of these new compounds against various bacterial and fungal strains were also investigated.
Collapse
|
8
|
Salvador LA, Luesch H. Discovery and mechanism of natural products as modulators of histone acetylation. Curr Drug Targets 2012; 13:1029-47. [PMID: 22594471 DOI: 10.2174/138945012802008973] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2011] [Revised: 01/30/2012] [Accepted: 05/15/2012] [Indexed: 12/31/2022]
Abstract
Small molecules that modulate histone acetylation by targeting key enzymes mediating this posttranslational modification - histone acetyltransferases and histone deacetylases - are validated chemotherapeutic agents for the treatment of cancer. This area of research has seen a rapid increase in interest in the past decade, with the structurally diverse natural products-derived compounds at its forefront. These secondary metabolites from various biological sources target this epigenetic modification through distinct mechanisms of enzyme regulation by utilizing a diverse array of pharmacophores. We review the discovery of these compounds and discuss their modes of inhibition together with their downstream biological effects.
Collapse
Affiliation(s)
- Lilibeth A Salvador
- Department of Medicinal Chemistry, University of Florida, Gainesville, 32610, USA
| | | |
Collapse
|
9
|
Iovanna J, Mallmann MC, Gonçalves A, Turrini O, Dagorn JC. Current knowledge on pancreatic cancer. Front Oncol 2012; 2:6. [PMID: 22655256 PMCID: PMC3356035 DOI: 10.3389/fonc.2012.00006] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Accepted: 01/11/2012] [Indexed: 12/12/2022] Open
Abstract
Pancreatic cancer is the fourth leading cause of cancer death with a median survival of 6 months and a dismal 5-year survival rate of 3-5%. The development and progression of pancreatic cancer are caused by the activation of oncogenes, the inactivation of tumor suppressor genes, and the deregulation of many signaling pathways. Therefore, the strategies targeting these molecules as well as their downstream signaling could be promising for the prevention and treatment of pancreatic cancer. However, although targeted therapies for pancreatic cancer have yielded encouraging results in vitro and in animal models, these findings have not been translated into improved outcomes in clinical trials. This failure is due to an incomplete understanding of the biology of pancreatic cancer and to the selection of poorly efficient or imperfectly targeted agents. In this review, we will critically present the current knowledge regarding the molecular, biochemical, clinical, and therapeutic aspects of pancreatic cancer.
Collapse
Affiliation(s)
- Juan Iovanna
- INSERM U624, Stress Cellulaire, Parc Scientifique et Technologique de LuminyMarseille, France
| | | | - Anthony Gonçalves
- Département d’Oncologie Médicale, Institut Paoli-CalmettesMarseille, France
| | - Olivier Turrini
- Département de Chirurgie Oncologique, Institut Paoli-CalmettesMarseille, France
| | - Jean-Charles Dagorn
- INSERM U624, Stress Cellulaire, Parc Scientifique et Technologique de LuminyMarseille, France
| |
Collapse
|
10
|
Kemp MM, Wang Q, Fuller JH, West N, Martinez NM, Morse EM, Weïwer M, Schreiber SL, Bradner JE, Koehler AN. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorg Med Chem Lett 2011; 21:4164-9. [PMID: 21696956 PMCID: PMC3248787 DOI: 10.1016/j.bmcl.2011.05.098] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Revised: 05/24/2011] [Accepted: 05/25/2011] [Indexed: 12/01/2022]
Abstract
Histone deacetylases (HDACs) are enzymes involved in many important biological functions. They have been linked to a variety of cancers, psychiatric disorders, and other diseases. Since small molecules can serve as probes to study the relevant biological roles of HDACs, novel scaffolds are necessary to develop more efficient, selective drug candidates. Screening libraries of molecules may yield structurally diverse probes that bind these enzymes and modulate their functions in cells. Here we report a small molecule with a novel hydroxy-pyrimidine scaffold that inhibits multiple HDAC enzymes and modulates acetylation levels in cells. Analogs were synthesized in an effort to evaluate structure-activity relationships.
Collapse
Affiliation(s)
| | - Qiu Wang
- Broad Institute of Harvard and MIT, Cambridge, MA 02142
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138
| | | | - Nathan West
- Broad Institute of Harvard and MIT, Cambridge, MA 02142
- The Dana-Farber Cancer Institute, Division of Hematologic Neoplasia, Boston, MA 02115
| | | | - Elizabeth M. Morse
- Broad Institute of Harvard and MIT, Cambridge, MA 02142
- The Dana-Farber Cancer Institute, Division of Hematologic Neoplasia, Boston, MA 02115
| | - Michel Weïwer
- Broad Institute of Harvard and MIT, Cambridge, MA 02142
| | - Stuart L. Schreiber
- Broad Institute of Harvard and MIT, Cambridge, MA 02142
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138
- Howard Hughes Medical Institute, Chevy Chase, MD 20815
| | - James E. Bradner
- Broad Institute of Harvard and MIT, Cambridge, MA 02142
- The Dana-Farber Cancer Institute, Division of Hematologic Neoplasia, Boston, MA 02115
| | | |
Collapse
|
11
|
Singh EK, Nazarova LA, Lapera SA, Alexander LD, McAlpine SR. Histone Deacetylase Inhibitors: Synthesis of Cyclic Tetrapeptides and their Triazole Analogues. Tetrahedron Lett 2010; 51:4357-4360. [PMID: 20865132 DOI: 10.1016/j.tetlet.2010.06.050] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Synthesis of nine macrocyclic peptide HDAC inhibitors and three triazole derivatives are described. HDAC inhibitory activity of these compounds against HeLa cell lysate is evaluated. The biological data demonstrates that incorporation of a triazole unit improves the HDAC inhibitory activity.
Collapse
Affiliation(s)
- Erinprit K Singh
- Department of Chemistry and Biochemistry, 5500 Campanile Dr., San Diego State University, San Diego, CA 92182-1030
| | | | | | | | | |
Collapse
|
14
|
The sunset of somatic genetics and the dawn of epigenetics: a new frontier in pancreatic cancer research. Curr Opin Gastroenterol 2008; 24:597-602. [PMID: 19122501 PMCID: PMC2941574 DOI: 10.1097/mog.0b013e32830b111d] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
PURPOSE OF REVIEW The excitement of finding a cancer modulator which is either mutated or deleted in vivo (genetics), unfortunately, is shadowed by the fact that we scientists have failed to live to the promise of gene therapy, and therefore, these genes cannot be replaced to cure the patients. On the contrary, both DNA methylation and chromatin-mediated inactivation of tumor suppressor genes (epigenetics), for example, are reversible as demonstrated by the relative success of emerging therapies. Therefore, epigenetics with its molecular basis (DNA methylation and chromatin modification) is among the most promising areas of cancer research and is a nascent field in pancreatic cancer research. RECENT FINDINGS Here, we review and update novel findings on epigenetics as it applies to pancreatic cancer. SUMMARY Special focus has been given to novel potential therapeutic targets and currently available drugs, which are emerging from this exciting new field of pancreatic cancer research.
Collapse
|